Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma To Adjourn Special Meeting To September 29, 2025
Brief: Essa Pharma Provides Update On Application To Supreme Court Of British Columbia For Approval Of Interim Order
Brief: ESSA Pharma Inc. Announces Definitive Agreement To Be Acquired By Xenotherapeutics, Inc., Backed By XOMA Royalty Corporation In All-Cash Transaction
Essa Pharma Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Essa Pharma Inc Expected To Post A Loss Of 17 Cents A Share: Earnings Preview
Brief: ESSA Pharma Reports Financial Results For Fiscal Second Quarter Ended March 31, 2025
Essa Pharma Inc Reports Results For The Quarter Ended December 31: Earnings Summary
Essa Pharma Inc Expected To Post A Loss Of 18 Cents A Share: Earnings Preview
Essa Pharma Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Essa Pharma Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview
Brief: Tang Capital Management, Llc Reports 9.7% Stake In Essa Pharma As Of Nov 1- SEC Filing
Brief: ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data
Essa Pharma Inc Reports Results For The Quarter Ended In June: Earnings Summary
Essa Pharma Inc Expected To Post A Loss Of 25 Cents A Share: Earnings Preview
Essa Pharma Inc Reports Results For The Quarter Ended In March: Earnings Summary